Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 7/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 6/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | ITK | Q08881 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FES | P07332 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999867 | 0.92 | GSK3A (0.53) | GSK3AGSK3BEGFRAURKAJAK2 | |
| SCHEMBL8999857 | 0.89 | GSK3A (0.53) | GSK3AGSK3BEGFRAURKAJAK2 | |
| SCHEMBL655277 | 0.84 | AURKA (0.48) | EGFRAURKASYKCDK2ITK | |
| SCHEMBL656605 | 0.84 | SYK (0.48) | EGFRAURKASYKCDK2ITK | |
| SCHEMBL21282231 | 0.83 | GSK3A (0.53) | GSK3AGSK3BEGFRAURKAJAK2 | |
| SCHEMBL23366154 | 0.82 | SYK (0.57) | GSK3AGSK3BEGFRAURKAJAK2 | |
| SCHEMBL656468 | 0.82 | EGFR (0.47) | EGFRSYKITKBTK | |
| SCHEMBL656929 | 0.81 | SYK (0.60) | EGFRAURKASYKITK | |
| SCHEMBL656927 | 0.81 | SYK (0.45) | EGFRAURKASYKCDK2ITK | |
| SCHEMBL656308 | 0.81 | SYK (0.62) | EGFRAURKASYKITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | GSK3A 2114/4885GSK3B 2088/4885EGFR 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.